Nov 20, 2026 · Science & Research Daily Digest
A roundup of today's science, spaceflight, biomedical and climate research news as of November 20, 2026, with summaries, links and commentary.
I. Space & Deep Space
1. Space | Voyager 1 Reaches One Light-Day From Earth; NASA Confirms the Signal
Summary:
NASA says Voyager 1 reached one light-day from Earth—about 25.9 billion kilometers (16.1 billion miles)—at 5:16 a.m. EST on November 18, becoming humanity's farthest-flying spacecraft. The JPL team confirmed the milestone via the craft's carrier signal 24 hours later; science and engineering data have been disrupted since November 14, and engineers are still investigating. Launched in 1977 and in interstellar space since 2012, the probe has been flying for nearly 50 years.
Links:
- NASA — Voyager 1 Makes History Reaching One Light-Day From Earth
- China News — Signal received from one light-day away
Commentary:
A light-day is a distance milestone that also underscores the dual challenge of interstellar latency and aging-spacecraft operations.
2. Space | BepiColombo Is About to Enter Mercury Orbit for a Close Look
Summary:
ESA and JAXA's BepiColombo mission is due to be captured into Mercury orbit on November 21, ending an eight-year journey of about 10 billion kilometers that included nine planetary flybys since the 2018 launch. Around December 9, ESA's Mercury Planetary Orbiter (MPO) and JAXA's Mercury Magnetospheric Orbiter (Mio) will separate into roughly two-hour and nine-hour polar orbits, with full science operations planned for April 2027.
Links:
Commentary:
These will be the first new Mercury visitors in more than a decade; orbital data will decide whether a future lander is scientifically justified.
3. Space | ESA Selects Plasma Observatory: Seven Spacecraft to Track Solar Energy in Earth's Magnetosphere
Summary:
ESA Member States selected Plasma Observatory as the agency's next medium-class science mission (M7). Seven coordinated spacecraft will, for the first time, track how the Sun's energy moves through Earth's magnetic shield across different spatial and temporal scales. Building on the Cluster quartet, launch is provisionally planned for the late 2030s; ESA also narrowed the next medium- and fast-class candidate lists to four and three missions, respectively.
Links:
Commentary:
Moving from four craft to seven is about simultaneous multi-scale sampling—the missing link between fine detail and the big picture of magnetospheric energy transfer.
4. Space | China Launches Low-Earth Orbit Satellite Internet Group 30 on Long March 8A
Summary:
At 19:59 on November 20, China launched Low-Earth Orbit Satellite Internet Group 30 from the Hainan commercial spaceport on a Long March 8A rocket; the satellites entered their planned orbits. Xinhua reported the successful mission from Wenchang, continuing constellation build-out from the commercial launch site.
Links:
Commentary:
LEO broadband launches are becoming routine; the next tests are constellation scale, spectrum coordination and ground-terminal rollout.
II. Biomedicine
5. Medicine | Updated Daraxonrasib-Plus-Chemo Data in First-Line Metastatic Pancreatic Cancer: ~61% Response Rate
Summary:
Revolution Medicines presented updated Phase 1/2 RMC-GI-102 results at the EORTC-NCI-AACR (ENA) meeting in Barcelona. As of September 28, 2026, 61 patients with treatment-naïve metastatic pancreatic adenocarcinoma received daraxonrasib (200 mg daily oral) plus gemcitabine and nab-paclitaxel. The confirmed objective response rate was 60.7% (including 8.2% complete responses), disease control was 90.2%, median progression-free survival was 12.8 months, and 12-month overall survival was 76.6%, with safety consistent with known profiles. The data support the ongoing global Phase 3 RASolute 303 trial.
Links:
- Revolution Medicines — Updated Phase 1/2 data for RASONQUE plus chemotherapy
- ecancer — Metastatic pancreatic cancer responds well to daraxonrasib plus chemotherapy
Commentary:
Early response rates look strong, but a single-arm design cannot prove superiority over chemotherapy alone—Phase 3 is the real test.
6. Medicine | Merck's Sac-TMT Meets Overall-Survival Primary Endpoint in Late-Line Gastroesophageal Adenocarcinoma
Summary:
Merck announced that the global Phase 3 TroFuse-015 trial of TROP2 antibody-drug conjugate sacituzumab tirumotecan (sac-TMT, licensed from Kelun-Biotech) met its overall-survival primary endpoint versus physician's-choice chemotherapy in locally advanced unresectable or metastatic gastroesophageal adenocarcinoma after two or more prior systemic regimens. The trial enrolled 473 patients; Merck says it is the first TROP2 ADC to show an OS benefit in this setting in a global Phase 3 study. Progression-free survival as a secondary endpoint was not statistically significant, and the safety profile matched prior studies. Data will go to a medical meeting and regulators.
Links:
Commentary:
An OS win without a PFS win suggests benefit may be more about survival than tumor-control duration; full data will shape labeling and practice.
7. Medicine | FDA Approves Livsayis (cemdisiran), the First siRNA Therapy for Generalized Myasthenia Gravis
Summary:
On November 18 the FDA approved Regeneron's Livsayis (cemdisiran) for anti-acetylcholine receptor antibody-positive adults with generalized myasthenia gravis—the first and only siRNA therapy in gMG, and the only option dosed subcutaneously four times a year. In Phase 3 NIMBLE, week-24 MG-ADL improved by about 2.3 points versus placebo, with functional benefit seen as early as week 2; labeling carries a boxed warning for serious meningococcal infection and requires a REMS. The molecule was discovered by Alnylam and advanced to approval by Regeneron.
Links:
- Regeneron — Livsayis approved as first siRNA therapy in gMG
- Healio — FDA approves Livsayis for generalized myasthenia gravis
Commentary:
C5 inhibition now spans monoclonal antibodies, nanobodies and siRNA; competition is shifting from efficacy to dosing frequency and adherence.
8. Health | Resistance Training Partly Offsets Muscle Loss From Obesity Drugs
Summary:
A Nature research highlight reports a clinical trial finding that thrice-weekly weightlifting can partially prevent muscle and strength loss during weight-loss drug treatment. The work focuses on middle-aged and older adults, suggesting structured resistance exercise may be a key companion intervention as GLP-1 and related obesity medicines spread.
Links:
Commentary:
Drug-driven weight loss and muscle preservation are not a trade-off to accept by default—exercise prescriptions belong in the care pathway.
III. Climate & Environment
9. Climate | Report Warns West Antarctic and Greenland Ice Sheets May Have Crossed Tipping Points
Summary:
Researchers at the University of Exeter and the British Antarctic Survey warn that, with global warming expected to exceed 1.5°C, the West Antarctic Ice Sheet (including the Amundsen Sea sector with Thwaites and Pine Island glaciers) and the Greenland Ice Sheet may already have crossed climate tipping points, with localized abrupt change also seen in some permafrost regions; the North Atlantic subpolar gyre may also have tipped. Full loss of those ice sheets could raise long-term sea level by about 5 m and 7 m, respectively. Authors urge faster cuts in short-lived climate pollutants such as methane and a shorter overshoot above 1.5°C.
Links:
- Xinhua — Polar ice sheets may have crossed climate tipping points
- Nature — Net zero emissions won’t reverse climate change
Commentary:
Tipping-point framing moves policy from whether to cut emissions to how fast to end overshoot and plan for multi-century coastal risk.
10. Environment | HKUST-Led Study Quantifies Atmospheric Organic Nitrogen: ~12.8 Million Tonnes a Year to the Oceans
Summary:
A team led by Hong Kong University of Science and Technology's Jianzhen Yu and Southern University of Science and Technology's Zongming Fu reports in Science that atmospheric organic nitrogen deposition to the global oceans is about 12.8 million tonnes per year—27% of total atmospheric nitrogen deposition, and up to about 50% in some nitrogen-limited seas—based on 418 marine aerosol samples from 21 cruises plus a global atmospheric chemistry model. Major sources include biomass burning, marine aerosol emissions and atmospherically formed imine compounds; non-marine sources account for about 70% of organic nitrogen deposition.
Links:
Commentary:
Quantifying a long-underestimated organic nitrogen fraction rewrites the input ledger for marine primary productivity and the global nitrogen cycle.
11. Energy | Rice University: Visible Light at Room Temperature Converts CO₂ Into Industrial Carbon Monoxide
Summary:
Rice University researchers demonstrated splitting carbon dioxide with visible light at room temperature. Peak performance under 475-nanometer blue light produced carbon monoxide at about 15,000 micromoles per hour per gram; the light-driven process ran steadily for about 238 minutes—nearly seven times longer than heat-driven controls that degraded within about 35 minutes—and yielded nearly three times more CO than materials lacking a cerium oxide "oxygen sponge." The route aims at lower-energy sustainable chemical manufacturing.
Links:
Commentary:
Room-temperature visible-light catalysis lowers the thermal barrier for CO₂ conversion; scale-up still hinges on catalyst lifetime and reactor engineering.
IV. Fundamental Research
12. Physics | MIT's Superconducting "Sandwich" Combines Cryogenic Nonvolatile Memory and Signal Control
Summary:
MIT Plasma Science and Fusion Center researchers report in Physical Review Letters a device sandwiching an ultrathin superconducting film between two magnetic layers. Brief heat pulses and a small magnetic field switch the film between superconducting and resistive states for nonvolatile cryogenic memory that needs no continuous power to hold a bit, and the same stack can act as a programmable diode for signal control. The authors say it could address the shortage of suitable cryogenic memory and control components for superconducting and quantum electronics.
Links:
Commentary:
For superconducting logic, memory often bottlenecks more than compute; a device demo is a key step, and array integration is next.
13. Physics | Yale Observes Massless, Light-Like Excitons in an Atom-Thin Material
Summary:
Yale researchers report in Nature Physics the first direct observation of massless excitons with light-like linear dispersion in monolayer hexagonal boron nitride, using momentum-resolved electron energy-loss spectroscopy (Q-EELS). The excitons moved at about 100,000 meters per second even though the constituent electrons and holes retained mass. The experiment also found monolayer hBN's optical bandgap wider than previously thought, with implications for quantum devices, photovoltaics and optoelectronics.
Links:
Commentary:
A decade-old theoretical prediction is now experimentally confirmed, giving 2D exciton physics a new photon-like transport path.
Today's Summary
- Space headlines centered on Voyager 1's one-light-day milestone, BepiColombo's imminent Mercury capture, and ESA's seven-craft Plasma Observatory selection.
- In biomedicine, updated RAS-targeted pancreatic cancer combination data ran alongside a TROP2 ADC overall-survival win in gastroesophageal cancer and the first siRNA approval for generalized myasthenia gravis.
- Climate and environment coverage paired ice-sheet tipping-point warnings with a quantified atmospheric organic-nitrogen flux and visible-light CO₂-to-CO catalysis.
- Fundamental physics advanced on two fronts: a cryogenic superconducting memory/control device and massless excitons in monolayer hBN.
Daily Framing:
Today in the science cycle was a "deep-space milestone meets translational medicine" day—interstellar distance records landed alongside clinically testable oncology and RNA-therapy checkpoints.
This digest is compiled from real-time search results and is for reference only.